JAMA: Moderna’s vaccine produced more antibodies than Pfizer’s

JAMA: Moderna’s vaccine produced more antibodies than Pfizer’s

This study demonstrated a significantly higher humoral immunogenicity of the SARS-CoV-2 mRNA-1273 vaccine (Moderna) compared with the BNT162b2 vaccine (Pfizer-BioNTech), in infected as well as uninfected participants, and across age categories. The higher mRNA content in mRNA-1273 compared with BNT162b2 and the longer interval between priming and boosting for mRNA-12733 (4 weeks vs 3 weeks for BNT162b2) might explain this difference.

A relationship between neutralization level after SARS-CoV-2 vaccination and protection against COVID-19 has been demonstrated by several studies.4 As such, the height of the humoral response after vaccination, which correlates with neutralizing antibody titers,5 might be clinically relevant.

Limitations of this study include the lack of data on cellular immunity and on neutralizing antibodies, as well as the specific focus on health care workers. Whether the observed difference in antibody level translates to a difference in the duration of protection,4 the protection against variants of concern, and the risk of transmission6 needs further investigation. Future research should also address the relevance for patients with reduced antibody response after vaccination.

Full study can be viewed here.